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Electrical isolation of the pulmonary veins (PV) by antral cre-
ation of transmural, continuous, and durable lesions by localized
cellular damage is the cornerstone of catheter based atrial fibrilla-
tion (AF) ablation procedures. Conventional radiofrequency (RF)
ablation with irrigated catheters involves delivery of relatively
low power (20–40W) for a relatively long duration (20–40 s)
(low-power long-duration (LP-LD)) at a contact force range of
10–20 g. Despite progress of PV isolation (PVI) ablation techniques,
AF recurrence, partially due to incomplete transmurality and/or
reversible injury, remains high with 20–40% [1].
RF ablation lesion formation can be split into two consecutive
phases. During the resistive phase, electrical current delivery via
the catheter tip heats the tissue surface. A heat source extends then
passively to deeper tissue layers during the conductive phase. Irre-
versible myocardial tissue injury with apoptosis and necrosis
occurs at temperatures above 50 C, whereas lower tissue temper-
atures often result in reversible tissue injury. Modifying the rela-
tionship between the resistive and conductive heating phases
may help to achieve safer and more effective uniform and trans-
mural lesions during PVI. For example, immediate heating to the
full thickness of the human PV circumference can be delivered
by increasing the resistive heating phase (higher power), and the
collateral tissue damage can be limited by reducing the conductive
heating phase by shortening the duration (shorter duration). These
biophysical concepts resulted in a high-power and short-duration
(HP-SD) ablation approach, that has been investigated in several
preclinical studies [2,3]. HP-SD results in less deep, but wider
and more contentious linear lesions [2,3]. Additionally, the abla-
tion procedure is much shorter as RF ablation lesions can be cre-
ated four-times faster when using 50W vs 30 W [4]. The steam
pop risks increase with power and time but delivering higher
energy for a shorter time at one spot overcomes the challenges
of catheter stability and tissue oedema, which makes the zone of
reversible injury smaller and allows lesion formation within a
shorter time [2].
Several prospective randomized and non-randomized studies
comparing LP-LD versus HP-SD show that HP-SD is associated with
higher first-pass PV isolation and significantly shorter procedural,
ablation and fluoroscopy times compared with LP-LD [5–10].
Meta-analysis data demonstrate that HP-SD was associated with
better procedural effectiveness when compared with conventional
LP-LD ablation with comparable low rate of complications and eso-
phageal thermal injury and shorter procedural duration [11,12].
Very HP-SD using 70 W for 5–7 s leads to significantly less arrhyth-
mia recurrences after 1 year [6]. Tilz et al. used 90 W for 4 s and
showed with this novel very HP-SD ablation mode a safe and effec-
tive PVI. Procedure duration and RF ablation time were substan-
tially shorter in comparison to the control group [5].
Despite promising observations with HP-SD and very HP-SD
ablations approaches, guiding energy delivery, in regard to power
and duration, remains the limiting factor for both safety (too much
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ablation) and efficacy (inappropriate limitation of ablation). It is
not clear which surrogate endpoints are best for HP-SD and direct
comparisons are difficult. Some traditionally used surrogate end-
points for LP-LD RF delivery include loss of bipolar electrogram
(EGM) voltage, change in unipolar EGM, impedance drop, loss of
capture or algorithms incorporating contact force, time and power.
However, these surrogate endpoints have been validated for LP-LD
and it remains unclear, whether they are also suitable for HP-SD.
For example, it is not clear that contact force has the same impact
on lesion prediction with HP-SD ablation compared to low-power
long-duration ablation. Contact is important, but the amount of
force from 5 to 30 g may not be since the duration is too short.
The same accounts for the prevention of collateral damage of struc-
tures around the left atrium such as the esophagus and the phrenic
nerve. The temporal resolution of commercially available temper-
ature probes for luminal esophageal temperature monitoring
may not adequately capture the early and quick temperature rise
to limit and guide RF delivery during HP-SD. A skilled operator
may place the 3rd HP-SD lesion before the luminal esophageal
temperature increase from the 1st lesion is fully recognized [4].
Better and accurate ‘‘real-time” monitoring of atrial lesion for-
mation or validated surrogate endpoints during the procedure pre-
dicting quality of the mature lesion are required guiding HP-SD
ablation procedures. Potentially, adding temperature rise and
micro-EGM changes may provide important information. The Dia-
mondTemp RF ablation catheter (Medtronic) was designed with a
diamond-embedded tip (for rapid cooling) and 6 surface thermo-
couples to reflect tissue temperature [12]. The high-resolution
EGMs from the split-tip electrode allows rapid lesion assessment.
The QDot Micro RF (Biosense Webster) ablation catheter incorpo-
rates three microelectrodes and six thermocouples allowing real-
time assessment of catheter-to-tissue interface temperature and
therefore temperature-controlled ablation. Another strategy might
be a tailored and dynamic power and duration setting guided by
the underlying anatomical structure, wall thickness and proximity
to surrounding anatomical structures derived by pre- or periproce-
dural imaging integrated in the 3D electroanatomical platform.
Such tailored anatomy-guided approach, which is already used to
guide radiation therapy in the cancer treatment (image-guided
radiation therapy), may help to improve the precision and accuracy
of energy delivery during interventional cardiac MRI procedures
[13].
In summary, emerging data show the feasibility, safety, and effi-
cacy of HP-SD modes for PVI. At the same time, this comes with a
spin-off benefit including shorter procedure times, less fluoroscopy
and shorter overall RF ablation time. However, the best setting for
HP-SD to minimize the risk of major complications while main-
taining maximal procedural efficacy remains controversial.
Whether approaches such as HP-SD (50 W) or very HP-SD (70W
or 90W) can increase the success rates of PVI procedures warrants
further prospective randomized study. Finally, in addition to focus-
ing on new more effective and safer ablation strategies alone, also
the systematic implementation of combined risk factor modifica-
tion programs is important to finally control sinus rhythm and
reduce the recurrence of AF after PVI procedures [14,15].
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